{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:24:58Z","timestamp":1771475098915,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T00:00:00Z","timestamp":1596672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T00:00:00Z","timestamp":1596672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 104-2321-B-006-036"],"award-info":[{"award-number":["MOST 104-2321-B-006-036"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hemodialysis patients have a high risk of mortality. The most common causes of death are cardiovascular disease and infection. The potential hazard or benefit associated with vitamin D use and cardiovascular or infection outcome is poorly characterized.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a retrospective observational cohort study by recruiting 52,757 patients older than 20\u2009years from Taiwan National Health Insurance Research Database (NHIRD) who initiated maintenance hemodialysis between 2001 and 2009. Patients who were prescribed activated vitamin D before the 360th day from hemodialysis initiation were defined as vitamin D users. The primary outcome of interest includes occurrence of acute myocardial infarction (AMI), ischemic stroke, lower limb amputation, and hospitalization for infection, respectively, while death events are treated as competing events. We conducted competing risk analysis using subdistribution hazard regression model to estimate subdistribution hazard ratios (SHRs) in relation to various outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During the median follow-up of 1019\u2009days, the vitamin D users had a lower crude mortality rate, lower incidences of AMI, ischemic stroke, amputation, and hospitalization for infection compared with non-users. Taking into consideration competing events of death, vitamin D users were associated with a lower hazard of lower limb amputation (SHR 0.84 [95% CI, 0.74\u20130.96]) and hospitalization for infection (SHR 0.90 [95% CI, 0.87\u20130.94]), but not AMI or ischemic stroke, after adjustment for potential confounders. Subgroup analyses and dose response evaluation both showed a consistent association of activated vitamin D treatment with decreased risk of amputation and infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The findings suggest that therapeutic activated vitamin D use in hemodialysis patients may be beneficial for decreasing infection events and amputation, of which the latter is a complication of peripheral vascular disease, rather than reducing major atherosclerotic cardiovascular events such as AMI or ischemic stroke.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-020-01988-2","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T11:02:57Z","timestamp":1596711777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The use of activated vitamin D and risks of hospitalization for infection and amputation in incident hemodialysis patients in Taiwan: a nationwide population-based cohort study"],"prefix":"10.1186","volume":"21","author":[{"given":"Jo-Yen","family":"Chao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4623-5561","authenticated-orcid":false,"given":"Yea-Huei","family":"Kao Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,6]]},"reference":[{"issue":"4","key":"1988_CR1","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1053\/j.ajkd.2011.04.028","volume":"58","author":"SD Navaneethan","year":"2011","unstructured":"Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Jain A, Schreiber MJ Jr, Simon JF, Srinivas TR, Nally JV Jr. Low 25-hydroxyvitamin D levels and mortality in non-dialysis-dependent CKD. Am J Kidney Dis. 2011;58(4):536\u201343.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"1988_CR2","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/sj.ki.5002451","volume":"72","author":"M Wolf","year":"2007","unstructured":"Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72(8):1004\u201313.","journal-title":"Kidney Int"},{"issue":"6","key":"1988_CR3","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.2215\/CJN.00260109","volume":"4","author":"DV Barreto","year":"2009","unstructured":"Barreto DV, Barreto FC, Liabeuf S, Temmar M, Boitte F, Choukroun G, Fournier A, Massy ZA. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1128\u201335.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"15","key":"1988_CR4","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1001\/archinte.168.15.1629","volume":"168","author":"ML Melamed","year":"2008","unstructured":"Melamed ML, Michos ED, Post W, Astor B. 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168(15):1629\u201337.","journal-title":"Arch Intern Med"},{"key":"1988_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1186\/s12879-015-1196-1","volume":"15","author":"S Esposito","year":"2015","unstructured":"Esposito S, Lelii M. Vitamin D and respiratory tract infections in childhood. BMC Infect Dis. 2015;15:487.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"1988_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/ki.2014.187","volume":"87","author":"N Abou-Hassan","year":"2015","unstructured":"Abou-Hassan N, Tantisattamo E, D'Orsi ET, O'Neill WC. The clinical significance of medial arterial calcification in end-stage renal disease in women. Kidney Int. 2015;87(1):195\u20139.","journal-title":"Kidney Int"},{"issue":"9","key":"1988_CR7","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/ndt\/gfg414","volume":"18","author":"GM London","year":"2003","unstructured":"London GM. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18(9):1731\u201340.","journal-title":"Nephrol Dial Transplant"},{"issue":"113","key":"1988_CR8","first-page":"S1","volume":"76","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease - mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009;76(113):S1\u2013130.","journal-title":"Kidney Int Suppl"},{"issue":"4","key":"1988_CR9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1001\/archinternmed.2007.110","volume":"168","author":"CP Kovesdy","year":"2008","unstructured":"Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med. 2008;168(4):397\u2013403.","journal-title":"Arch Intern Med"},{"issue":"3","key":"1988_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000346846","volume":"37","author":"F Duranton","year":"2013","unstructured":"Duranton F, Rodriguez-Ortiz ME, Duny Y, Rodriguez M, Daures JP, Argiles A. Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis. Am J Nephrol. 2013;37(3):239\u201348.","journal-title":"Am J Nephrol"},{"issue":"3","key":"1988_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10157-014-0994-x","volume":"19","author":"S Sueta","year":"2015","unstructured":"Sueta S, Morozumi K, Takeda A, Horike K, Otsuka Y, Shinjo H, Murata M, Kato Y, Goto K, Inaguma D, et al. Ability of vitamin D receptor activator to prevent pulmonary congestion in advanced chronic kidney disease. Clin Exp Nephrol. 2015;19(3):371\u20138.","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"1988_CR12","doi-asserted-by":"publisher","first-page":"358","DOI":"10.2215\/CJN.04040411","volume":"7","author":"ML Melamed","year":"2012","unstructured":"Melamed ML, Thadhani RI. Vitamin D therapy in chronic kidney disease and end stage renal disease. Clin J Am Soc Nephrol. 2012;7(2):358\u201365.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"1988_CR13","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1681\/ASN.2006060573","volume":"18","author":"GM London","year":"2007","unstructured":"London GM, Guerin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, Metivier F. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol. 2007;18(2):613\u201320.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1988_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11154-011-9195-z","volume":"13","author":"JH White","year":"2012","unstructured":"White JH. Vitamin D metabolism and signaling in the immune system. Rev Endocr Metab Disord. 2012;13(1):21\u20139.","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"1988_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1365-2265.2011.04261.x","volume":"76","author":"M Hewison","year":"2012","unstructured":"Hewison M. An update on vitamin D and human immunity. Clin Endocrinol. 2012;76(3):315\u201325.","journal-title":"Clin Endocrinol"},{"issue":"6","key":"1988_CR16","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.2215\/CJN.08871010","volume":"6","author":"Y Tsujimoto","year":"2011","unstructured":"Tsujimoto Y, Tahara H, Shoji T, Emoto M, Koyama H, Ishimura E, Tabata T, Nishizawa Y, Inaba M. Active vitamin D and acute respiratory infections in dialysis patients. Clin J Am Soc Nephrol. 2011;6(6):1361\u20137.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1988_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s12882-018-1111-2","volume":"19","author":"J-Y Chao","year":"2018","unstructured":"Chao J-Y, Chien H-C, Kuo T-H, Chang Y-T, Li C-Y, Wang M-C, Kao Yang Y-H. Assessing the effect of oral activated vitamin D on overall survival in hemodialysis patients: a landmark analysis. BMC Nephrol. 2018;19(1):309.","journal-title":"BMC Nephrol"},{"issue":"2","key":"1988_CR18","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/aje\/kwp107","volume":"170","author":"B Lau","year":"2009","unstructured":"Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol. 2009;170(2):244\u201356.","journal-title":"Am J Epidemiol"},{"issue":"26","key":"1988_CR19","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1002\/sim.7019","volume":"35","author":"X Mi","year":"2016","unstructured":"Mi X, Hammill BG, Curtis LH, Lai EC, Setoguchi S. Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study. Stat Med. 2016;35(26):4824\u201336.","journal-title":"Stat Med"},{"issue":"3","key":"1988_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/pds.1357","volume":"16","author":"S Suissa","year":"2007","unstructured":"Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007;16(3):241\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1988_CR21","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1977","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. Toronto: Academic Press, Inc.; 1977. [chapter 2]."},{"issue":"6","key":"1988_CR22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","volume":"133","author":"PC Austin","year":"2016","unstructured":"Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133(6):601\u20139.","journal-title":"Circulation"},{"issue":"8","key":"1988_CR23","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jamainternmed.2018.2436","volume":"178","author":"D Franz","year":"2018","unstructured":"Franz D, Zheng Y, Leeper NJ, Chandra V, Montez-Rath M, Chang TI. Trends in rates of lower extremity amputation among patients with end-stage renal Disease who receive Dialysis. JAMA Intern Med. 2018;178(8):1025\u201332.","journal-title":"JAMA Intern Med"},{"key":"1988_CR24","doi-asserted-by":"crossref","unstructured":"Harding JL, Pavkov ME, Gregg EW, Burrows NR. Trends of nontraumatic lower extremity amputation in end-stage renal disease and diabetes, United States, 2000\u20132015. Diabetes Care. 2019;42(8):1430-35.","DOI":"10.2337\/dc19-0296"},{"issue":"5","key":"1988_CR25","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2215\/CJN.01290308","volume":"3","author":"LS Dalrymple","year":"2008","unstructured":"Dalrymple LS, Go AS. Epidemiology of acute infections among patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(5):1487\u201393.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"1988_CR26","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2215\/CJN.02120508","volume":"3","author":"K Amann","year":"2008","unstructured":"Amann K. Media calcification and intima calcification are distinct entities in chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(6):1599\u2013605.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"1988_CR27","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1093\/ndt\/gfq650","volume":"26","author":"C Garcia-Canton","year":"2011","unstructured":"Garcia-Canton C, Bosch E, Ramirez A, Gonzalez Y, Auyanet I, Guerra R, Perez MA, Fernandez E, Toledo A, Lago M, et al. Vascular calcification and 25-hydroxyvitamin D levels in non-dialysis patients with chronic kidney disease stages 4 and 5. Nephrol Dial Transplant. 2011;26(7):2250\u20136.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"1988_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090201","volume":"9","author":"CL Huang","year":"2014","unstructured":"Huang CL, Wu IH, Wu YW, Hwang JJ, Wang SS, Chen WJ, Lee WJ, Yang WS. Association of lower extremity arterial calcification with amputation and mortality in patients with symptomatic peripheral artery disease. PLoS One. 2014;9(2):e90201.","journal-title":"PLoS One"},{"issue":"3","key":"1988_CR29","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jvs.2010.09.070","volume":"53","author":"T Ohtake","year":"2011","unstructured":"Ohtake T, Oka M, Ikee R, Mochida Y, Ishioka K, Moriya H, Hidaka S, Kobayashi S. Impact of lower limbs' arterial calcification on the prevalence and severity of PAD in patients on hemodialysis. J Vasc Surg. 2011;53(3):676\u201383.","journal-title":"J Vasc Surg"},{"key":"1988_CR30","doi-asserted-by":"publisher","first-page":"S130","DOI":"10.1046\/j.1523-1755.1999.07132.x","volume":"56","author":"CA Herzog","year":"1999","unstructured":"Herzog CA. Acute myocardial infarction in patients with end-stage renal disease. Kidney Int. 1999;56:S130\u20133.","journal-title":"Kidney Int"},{"issue":"4","key":"1988_CR31","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1097\/01.ASN.0000119144.95922.C4","volume":"15","author":"RN Foley","year":"2004","unstructured":"Foley RN. Septicemia in the United States Dialysis population, 1991 to 1999. J Am Soc Nephrol. 2004;15(4):1038\u201345.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"1988_CR32","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1086\/424516","volume":"39","author":"SJ Berman","year":"2004","unstructured":"Berman SJ, Johnson EW, Nakatsu C, Alkan M, Chen R, LeDuc J. Burden of infection in patients with end-stage renal disease requiring long-term dialysis. Clin Infect Dis. 2004;39(12):1747\u201353.","journal-title":"Clin Infect Dis"},{"key":"1988_CR33","doi-asserted-by":"publisher","first-page":"41170","DOI":"10.1038\/srep41170","volume":"7","author":"Y Obi","year":"2017","unstructured":"Obi Y, Hamano T, Wada A, Tsubakihara Y, Committee of Renal Data Registry of the Japanese Society for Dialysis T. Vitamin D receptor activator use and cause-specific death among dialysis patients: a nationwide cohort study using coarsened exact matching. Sci Rep. 2017;7:41170.","journal-title":"Sci Rep"},{"issue":"3","key":"1988_CR34","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/pds.3576","volume":"23","author":"I Normand","year":"2014","unstructured":"Normand I, Elftouh N, Laurin LP, Ouimet D, Harrak H, Lafrance JP. Association between vitamin D receptor activator and the risk of infection-related hospitalizations among incident hemodialysis patients: a nested case-control study. Pharmacoepidemiol Drug Saf. 2014;23(3):261\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"1988_CR35","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/1078-0432.CCR-11-2097","volume":"18","author":"JJ Dignam","year":"2012","unstructured":"Dignam JJ, Zhang Q, Kocherginsky M. The use and interpretation of competing risks regression models. Clin Cancer Res. 2012;18(8):2301\u20138.","journal-title":"Clin Cancer Res"},{"issue":"27","key":"1988_CR36","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1002\/sim.7501","volume":"36","author":"PC Austin","year":"2017","unstructured":"Austin PC, Fine JP. Practical recommendations for reporting Fine-gray model analyses for competing risk data. Stat Med. 2017;36(27):4391\u2013400.","journal-title":"Stat Med"},{"issue":"4","key":"1988_CR37","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0895-4356(00)00314-0","volume":"54","author":"R Bender","year":"2001","unstructured":"Bender R, Lange S. Adjusting for multiple testing\u2014when and how? J Clin Epidemiol. 2001;54(4):343\u20139.","journal-title":"J Clin Epidemiol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01988-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-020-01988-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01988-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T23:26:35Z","timestamp":1628205995000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-01988-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,6]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1988"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-01988-2","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,6]]},"assertion":[{"value":"24 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board (IRB) of National Cheng Kung University Hospital (IRB number: A-EX-106-038).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"331"}}